Get the Stockscreener App
44.76
5.05%
-2.38
Tarsus Pharmaceuticals Inc stock is traded at $44.76, with a volume of 529.64K.
It is down -5.05% in the last 24 hours and down -2.42% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$47.14
Open:
$47.11
24h Volume:
529.64K
Relative Volume:
0.82
Market Cap:
$1.99B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-9.6466
EPS:
-4.64
Net Cash Flow:
$-123.00M
1W Performance:
-5.49%
1M Performance:
-2.42%
6M Performance:
-9.43%
1Y Performance:
+31.49%
1-Day Range:
$44.60
$47.32
1-Week Range:
$44.60
$48.31
52-Week Range:
$20.08
$57.28
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
44.76 | 1.99B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Tarsus to Participate in Upcoming Investor Conferences | TARS St - GuruFocus
Tarsus to Participate in Upcoming Investor Conferences - GlobeNewswire
Tarsus Pharmaceuticals Reports First Quarter 2025 Sales Growth - VisionMonday.com
Tarsus Pharmaceuticals anticipates 85,000-90,000 XDEMVY bottles dispensed in Q2 2025 amid expanded DTC campaign - MSN
TARS: Goldman Sachs Updates Price Target for Tarsus Pharmaceuticals | TARS Stock News - GuruFocus
Tarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to Analysts - Yahoo Finance
6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know - Benzinga
Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal - Benzinga
Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown - Quantisnow
How to Take Advantage of moves in (TARS) - news.stocktradersdaily.com
Analysts Just Made A Substantial Upgrade To Their Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Forecasts - Yahoo Finance
Tarsus Pharmaceuticals Insiders Sold US$3.9m Of Shares Suggesting Hesitancy - simplywall.st
Decoding Tarsus Pharmaceuticals Inc (TARS): A Strategic SWOT Ins - GuruFocus
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates - MSN
Tarsus Pharmaceuticals’ Earnings Call Highlights Robust Growth - TipRanks
TARS: Guggenheim Raises Price Target for Tarsus Pharmaceuticals - GuruFocus
TARS: Guggenheim Boosts Price Target After Q1 Update | TARS Stoc - GuruFocus
Tarsus Pharmaceuticals Inc (TARS) Q1 2025 Earnings Call Highlights: Record Sales Surge and ... - Yahoo Finance
Tarsus Pharmaceuticals Reports Strong Q1 2025 Growth - TipRanks
Tarsus Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements - ADVFN
Tarsus Pharmaceuticals (TARS) Q1 Earnings: EPS of $(0.64) Beats Estimate, Revenue Surges to $78.3 Million - GuruFocus
TARS Surpasses Revenue Expectations in First Quarter | TARS Stoc - GuruFocus
Tarsus Pharmaceuticals (TARS) Reports Strong Q1 2025 Sales Growt - GuruFocus
Earnings call transcript: Tarsus Pharmaceuticals Q1 2025 sees robust sales growth - Investing.com
Tarsus Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:TARS) - Seeking Alpha
TARS Surpasses Revenue Expectations in First Quarter | TARS Stock News - GuruFocus
Earnings Flash (TARS) Tarsus Pharmaceuticals Reports Q1 Loss $-0.64 Per Share, vs. FactSet Est of $-0.78 - marketscreener.com
Ready to Jump After Recent Trade: Tarsus Pharmaceuticals Inc (TARS) - Sete News
Tarsus to Report First Quarter 2025 Financial Results on Thursda - GuruFocus
BlackRock, Inc. Reduces Stake in Tarsus Pharmaceuticals Inc. - GuruFocus
Tarsus Pharmaceuticals Inc (TARS) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
An Overview of Tarsus Pharmaceuticals's Earnings - Nasdaq
Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High? - Yahoo Finance
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of “Buy” by Brokerages - Defense World
LPL Financial LLC Sells 5,125 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Analysts Say That Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Is Likely To Make It To 72 In 12 Months - Marketing Sentinel
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 - The Manila Times
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 - GlobeNewswire Inc.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Wells Fargo & Company MN - Defense World
Commit To Buy Tarsus Pharmaceuticals At $40, Earn 13.3% Annualized Using Options - Nasdaq
Tarsus Pharmaceuticals (TARS) Highlights Global Impact of Demodex Blepharitis at ASCRS 2025 | TARS Stock News - GuruFocus
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting - GlobeNewswire
Tarsus to Present Several Scientific Abstracts Highlighting the - GuruFocus
Learn to Evaluate (TARS) using the Charts - news.stocktradersdaily.com
Franklin Resources Inc. Sells 2,404 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by JPMorgan Chase & Co. - Defense World
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Surging 33.69% In 6 Months – Here’s What To Expect - Marketing Sentinel
Midday Stock Roundup: Healthcare, medtech stocks tumble - Orange County Business Journal
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by Vanguard Group Inc. - Defense World
Papulopustular Rosacea Market Expected to Experience Major Growth by 2034, According to DelveInsight | Sol-Gel Technologies, Galderma, CollaGenex Pharma, Tarsus Pharma, Pfizer - Barchart.com
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):